ibuprofen has been researched along with Cholera Infantum in 60 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate the effects of acute ibuprofen consumption (2 × 600-mg doses) on markers of enterocyte injury, intestinal barrier dysfunction, inflammation, and symptoms of gastrointestinal (GI) distress at rest and after exercise in hypobaric hypoxia." | 9.69 | Ibuprofen Increases Markers of Intestinal Barrier Injury But Suppresses Inflammation at Rest and After Exercise in Hypoxia. ( Amorim, FT; Berkemeier, QN; Deyhle, MR; Ducharme, JB; Fennel, ZJ; Gillum, TL; McKenna, ZJ; Mermier, CM; Specht, JW, 2023) |
| "To investigate short-term efficacy and safety of a novel lipid ibuprofen formulation 1200 mg/day compared with standard ibuprofen 1200 mg/day and 2400 mg/day in episodic knee arthralgia/flaring pain." | 9.24 | A new lipid formulation of low dose ibuprofen shows non-inferiority to high dose standard ibuprofen: the FLARE study (flaring arthralgia relief evaluation in episodic flaring knee pain) - a randomised double-blind study. ( Bierma-Zeinstra, SMA; Brew, J; Conaghan, PG; Kilbourn, A; Stoner, K; Wilson, R, 2017) |
| "Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen." | 9.22 | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016) |
| "Despite a wide range of study designs, a multiplicity of international trials of diclofenac in osteoarthritis have disclosed similar results." | 9.06 | International experiences with diclofenac in osteoarthritis. ( Altman, R, 1986) |
| "A prospective evaluation of the efficacy and safety of oral ibuprofen and tetracycline hydrochloride was conducted for 8 weeks in patients with moderately severe acne." | 9.05 | Oral ibuprofen and tetracycline for the treatment of acne vulgaris. ( Ellis, CN; Heezen, JL; Kang, S; Voorhees, JJ; Wong, RC, 1984) |
| "A total of 120 general practice patients with osteoarthritis of the knee or hip received either benoxaprofen 600 mg mane or ibuprofen 400 mg tid for 4 months in a double-blind, parallel trial." | 9.05 | A comparative study of benoxaprofen and ibuprofen in osteoarthritis in general practice. ( Glynne, A; Tyson, VC, 1980) |
| "In a double-blind, multiclinic study, 437 patients with osteoarthritis were treated sequentially with ibuprofen, 1,800 mg/day, and placebo, or with aspirin, 3,600 mg/day, and placebo." | 9.04 | Ibuprofen in osteoarthritis. ( Brooks, CD; Donaldson, MS; Giansiracusa, JE; Koonce, ML; Lefton, TE; Ruoff, GE, 1977) |
| "Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited." | 8.87 | Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 7.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| " We compared the 3-month direct medical costs, including those associated with treating NSAID-induced adverse events, of nabumetone, ibuprofen, or ibuprofen plus misoprostol in 171 elderly patients with osteoarthritis." | 7.69 | Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol. ( Baker, AM; Bentkover, JD; Kaplan, H, 1994) |
| "To determine whether celecoxib, a COX-2-specific inhibitor, is associated with a lower incidence of significant upper GI toxic effects and other adverse effects compared with conventional NSAIDs." | 6.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| "Naproxen-treated patients experienced significantly (p < 0." | 6.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| "The purpose of this study was to evaluate the effects of acute ibuprofen consumption (2 × 600-mg doses) on markers of enterocyte injury, intestinal barrier dysfunction, inflammation, and symptoms of gastrointestinal (GI) distress at rest and after exercise in hypobaric hypoxia." | 5.69 | Ibuprofen Increases Markers of Intestinal Barrier Injury But Suppresses Inflammation at Rest and After Exercise in Hypoxia. ( Amorim, FT; Berkemeier, QN; Deyhle, MR; Ducharme, JB; Fennel, ZJ; Gillum, TL; McKenna, ZJ; Mermier, CM; Specht, JW, 2023) |
| " Given the low rates of events, at low or intermittent dosage without concurrent treatment, these 3 analgesics cannot be distinguished from each other or from background rates of serious GI toxicity." | 5.32 | Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. ( Bruce, B; Fries, JF, 2003) |
| " Osteoarthritis or rheumatoid arthritis patients, needing ongoing NSAID treatment, were randomised to receive celecoxib 100-200 mg b." | 5.27 | Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. ( Bao, W; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Nissen, SE; Solomon, DH; Stevens, T; Vargo, J; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018) |
| "To determine the relative risks of cardiovascular (CV), gastrointestinal (GI), and renal adverse events during long-term treatment with celecoxib, compared with ibuprofen and naproxen, in patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA)." | 5.27 | Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. ( Bao, W; Berger, MF; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018) |
| "To investigate short-term efficacy and safety of a novel lipid ibuprofen formulation 1200 mg/day compared with standard ibuprofen 1200 mg/day and 2400 mg/day in episodic knee arthralgia/flaring pain." | 5.24 | A new lipid formulation of low dose ibuprofen shows non-inferiority to high dose standard ibuprofen: the FLARE study (flaring arthralgia relief evaluation in episodic flaring knee pain) - a randomised double-blind study. ( Bierma-Zeinstra, SMA; Brew, J; Conaghan, PG; Kilbourn, A; Stoner, K; Wilson, R, 2017) |
| "Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen." | 5.22 | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016) |
| "The objective of this study is to utilize a clinical trial based on a decision-analysis model to assess the economic benefit of a lower incidence of gastrointestinal lesions in elderly patients with osteoarthritis receiving nabumetone therapy compared with ibuprofen alone and in combination with misoprostol." | 5.07 | A decision analysis model in the evaluation of NSAIDs in a managed care setting: a case study. ( Brixner, DI, 1994) |
| "Despite a wide range of study designs, a multiplicity of international trials of diclofenac in osteoarthritis have disclosed similar results." | 5.06 | International experiences with diclofenac in osteoarthritis. ( Altman, R, 1986) |
| "A prospective evaluation of the efficacy and safety of oral ibuprofen and tetracycline hydrochloride was conducted for 8 weeks in patients with moderately severe acne." | 5.05 | Oral ibuprofen and tetracycline for the treatment of acne vulgaris. ( Ellis, CN; Heezen, JL; Kang, S; Voorhees, JJ; Wong, RC, 1984) |
| "A total of 120 general practice patients with osteoarthritis of the knee or hip received either benoxaprofen 600 mg mane or ibuprofen 400 mg tid for 4 months in a double-blind, parallel trial." | 5.05 | A comparative study of benoxaprofen and ibuprofen in osteoarthritis in general practice. ( Glynne, A; Tyson, VC, 1980) |
| "Adverse experiences were monitored in 1,681 patients with rheumatoid arthritis (RA) or osteoarthritis to evaluate the safety of benoxaprofen at daily doses up to 1,000 mg during long-term therapy." | 5.05 | Long-term safety of benoxaprofen. ( Mikulaschek, WM, 1980) |
| "Ninety patients with rheumatoid arthritis completed a double-blind crossover trial comparing fenoprofen, ibuprofen, ketoprofen, and naproxen." | 5.04 | Four new anti-inflammatory drugs: responses and variations. ( Balme, HW; Franklin, S; Huskisson, EC; Scott, J; Woolf, DL, 1976) |
| "In a double-blind, multiclinic study, 437 patients with osteoarthritis were treated sequentially with ibuprofen, 1,800 mg/day, and placebo, or with aspirin, 3,600 mg/day, and placebo." | 5.04 | Ibuprofen in osteoarthritis. ( Brooks, CD; Donaldson, MS; Giansiracusa, JE; Koonce, ML; Lefton, TE; Ruoff, GE, 1977) |
| "Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited." | 4.87 | Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011) |
| " In a cohort study comparing the risk of upper gastrointestinal complications in celecoxib or traditional NSAIDs (diclofenac, ibuprofen) initiators with rheumatoid arthritis and osteoarthritis, we (1) aggregated medications and International Classification of Diseases-9 (ICD-9) diagnoses into hierarchies of the Anatomical Therapeutic Chemical classification (ATC) and the Clinical Classification Software (CCS), respectively, and (2) sampled the full cohort using techniques validated by simulations to create 9,600 samples to compare 16 aggregation scenarios across 50% and 20% samples with varying outcome incidence and exposure prevalence." | 3.79 | Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. ( Beach, KJ; Brookhart, MA; Layton, JB; Le, HV; Poole, C; Schoenbach, VJ; Stürmer, T, 2013) |
| "A meta-analysis was performed to compare the incidence of adverse experiences (AEs) during the multiple-dose use of nonprescription ibuprofen to a placebo." | 3.79 | The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis. ( Binstok, G; Cooper, SA; Furey, SA; Kellstein, DE; Waksman, JA, 1999) |
| "Phospho-aspirin, phospho-ibuprofen and phospho-sulindac were safer than their parent NSAIDs, were highly effective in rat adjuvant arthritis and inhibited many key mediators in the pathophysiology of RA." | 3.77 | The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. ( Huang, L; Johnson, F; Komninou, D; Mackenzie, G; Ouyang, N; Rigas, B; Sun, Y; Xie, G, 2011) |
| "To simultaneously assess the short-term reduction in risk of gastrointestinal (GI) complications and increase in risk of acute myocardial infarction (MI) by celecoxib compared with rofecoxib and several nonselective nonsteroidal antiinflammatory drugs (NSAIDs) using instrumental variable analysis." | 3.73 | Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. ( Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS, 2006) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 3.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| " We compared the 3-month direct medical costs, including those associated with treating NSAID-induced adverse events, of nabumetone, ibuprofen, or ibuprofen plus misoprostol in 171 elderly patients with osteoarthritis." | 3.69 | Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol. ( Baker, AM; Bentkover, JD; Kaplan, H, 1994) |
| "Repeat oral dosing of nabumetone for 1 month maintains anti-inflammatory efficacy in a carrageenan model of paw oedema yet does not cause gastrointestinal damage." | 3.68 | Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac. ( Blower, PR; Gentry, C; Melarange, R; O'Connell, C, 1991) |
| " Gastrointestinal adverse drug reactions were reported in 8 patients (3." | 2.79 | Comparison of safety, efficacy and tolerability of dexibuprofen and ibuprofen in the treatment of osteoarthritis of the hip or knee. ( Böttcher, E; Eller, N; Hawel, R; Mitterhuber, J; Rieger, JD; Stallinger, S; Zamani, O, 2014) |
| "Ibuprofen liquigel is an encapsulated, solubilized potassium salt of ibuprofen that has a higher Cmax and shorter tmax than traditional ibuprofen solid-dosage formulations." | 2.70 | Efficacy and tolerability of nonprescription ibuprofen versus celecoxib for dental pain. ( Ashraf, E; Cooper, SA; Doyle, G; Jayawardena, S, 2002) |
| " Trials and spontaneously reported adverse experiences suggest that gastrointestinal symptoms and bleeding are rare." | 2.69 | Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. ( Ashraf, E; Baird, L; Berlin, R; Cooper, S; Doyle, G; Furey, S; Jayawardena, S, 1999) |
| "To determine whether celecoxib, a COX-2-specific inhibitor, is associated with a lower incidence of significant upper GI toxic effects and other adverse effects compared with conventional NSAIDs." | 2.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| "Naproxen-treated patients experienced significantly (p < 0." | 2.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| " Documentation is derived from clinical trials, post-marketing surveillance, special studies, and spontaneous reports of adverse drug reactions from foreign countries." | 2.66 | Worldwide safety experience with diclofenac. ( Catalano, MA, 1986) |
| "Since its introduction in the United States in 1974, ibuprofen (Motrin, Upjohn) has been shown to be safe and effective for the treatment of pain, dysmenorrhea, inflammation, and fever." | 2.65 | Safety profile: fifteen years of clinical experience with ibuprofen. ( Royer, GL; Seckman, CE; Welshman, IR, 1984) |
| "Ibuprofen is a widely used antipyretic and analgesic nonsteroidal antiinflammatory drug (NSAID)." | 2.46 | Ibuprofen-induced hypersensitivity syndrome. ( Nanau, RM; Neuman, MG, 2010) |
| " However, adverse effects should be taken into account in the choice between ibuprofen and acetaminophen." | 2.44 | [Ibuprofen in childhood: evidence-based review of efficacy and safety]. ( Cosson, MA; Landre-Peigne, C; Leroy, S; Mosca, A; Pons, G, 2007) |
| " Etoricoxib is partly metabolised by the cytochrome P450 isoenzyme CYP 3A4 and increases the bioavailability of ethinylestradiol." | 1.34 | Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain. ( , 2007) |
| " Subjects were eligible for inclusion in the study if they received an OTC dosage of naproxen (220 mg) or ibuprofen (200 mg)." | 1.33 | Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. ( Biskupiak, JE; Brixner, DI; Howard, K; Oderda, GM, 2006) |
| " However, user ability to discover the most common side effect to the drug seemed not to be affected." | 1.32 | Awareness and frequency of potential side effects on nonsteroidal anti-inflammatory drugs among the Jordanian patient population. ( Abdel-Hafiz, SM; Al-Safi, SA; Albsoul-Younes, AM; Jabateh, SK, 2004) |
| " Given the low rates of events, at low or intermittent dosage without concurrent treatment, these 3 analgesics cannot be distinguished from each other or from background rates of serious GI toxicity." | 1.32 | Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. ( Bruce, B; Fries, JF, 2003) |
| " This molecular modification may offer a general route to safer antiinflammatory agents, potentially suitable for chronic use in conditions such as neurodegenerative disorders." | 1.32 | Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity. ( Charitos, C; Doulgkeris, C; Galanakis, D; Gavalas, A; Kourounakis, AP; Kourounakis, PN; Kravaritou, C; Rekka, EA; Tsiakitzis, KC, 2004) |
| " Although this study failed to describe a dose-response relationship, it appears that there are significant breed differences in susceptibility to GIU subsequent to ibuprofen exposure." | 1.30 | A case-control study of acute ibuprofen toxicity in dogs. ( Hungerford, LL; Poortinga, EW, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (20.00) | 18.7374 |
| 1990's | 10 (16.67) | 18.2507 |
| 2000's | 21 (35.00) | 29.6817 |
| 2010's | 16 (26.67) | 24.3611 |
| 2020's | 1 (1.67) | 2.80 |
| Authors | Studies |
|---|---|
| Galanakis, D | 1 |
| Kourounakis, AP | 2 |
| Tsiakitzis, KC | 1 |
| Doulgkeris, C | 1 |
| Rekka, EA | 2 |
| Gavalas, A | 1 |
| Kravaritou, C | 1 |
| Charitos, C | 1 |
| Kourounakis, PN | 2 |
| Siskou, IC | 1 |
| Chrysselis, MC | 1 |
| Tsiakitzis, K | 1 |
| McKenna, ZJ | 1 |
| Ducharme, JB | 1 |
| Berkemeier, QN | 1 |
| Specht, JW | 1 |
| Fennel, ZJ | 1 |
| Gillum, TL | 1 |
| Deyhle, MR | 1 |
| Amorim, FT | 1 |
| Mermier, CM | 1 |
| Martini, S | 1 |
| Aceti, A | 1 |
| Galletti, S | 1 |
| Beghetti, I | 1 |
| Faldella, G | 1 |
| Corvaglia, L | 1 |
| Moore, A | 1 |
| Crossley, A | 1 |
| Ng, B | 1 |
| Phillips, L | 1 |
| Sancak, Ö | 1 |
| Rainsford, KD | 1 |
| Bierma-Zeinstra, SMA | 1 |
| Brew, J | 1 |
| Stoner, K | 1 |
| Wilson, R | 1 |
| Kilbourn, A | 1 |
| Conaghan, PG | 1 |
| Solomon, DH | 4 |
| Husni, ME | 3 |
| Wolski, KE | 3 |
| Wisniewski, LM | 3 |
| Borer, JS | 3 |
| Graham, DY | 3 |
| Libby, P | 3 |
| Lincoff, AM | 3 |
| Lüscher, TF | 3 |
| Menon, V | 2 |
| Yeomans, ND | 3 |
| Wang, Q | 3 |
| Bao, W | 3 |
| Berger, MF | 2 |
| Nissen, SE | 3 |
| Stevens, T | 1 |
| Vargo, J | 1 |
| Walker, C | 1 |
| Bhala, N | 1 |
| Emberson, J | 1 |
| Merhi, A | 1 |
| Abramson, S | 1 |
| Arber, N | 1 |
| Baron, JA | 2 |
| Bombardier, C | 1 |
| Cannon, C | 1 |
| Farkouh, ME | 1 |
| FitzGerald, GA | 1 |
| Goss, P | 1 |
| Halls, H | 1 |
| Hawk, E | 1 |
| Hawkey, C | 1 |
| Hennekens, C | 1 |
| Hochberg, M | 1 |
| Holland, LE | 1 |
| Kearney, PM | 1 |
| Laine, L | 1 |
| Lanas, A | 2 |
| Lance, P | 1 |
| Laupacis, A | 1 |
| Oates, J | 1 |
| Patrono, C | 1 |
| Schnitzer, TJ | 1 |
| Solomon, S | 1 |
| Tugwell, P | 1 |
| Wilson, K | 1 |
| Wittes, J | 1 |
| Baigent, C | 1 |
| Le, HV | 1 |
| Poole, C | 1 |
| Brookhart, MA | 2 |
| Schoenbach, VJ | 1 |
| Beach, KJ | 1 |
| Layton, JB | 1 |
| Stürmer, T | 1 |
| Tuskey, A | 1 |
| Peura, D | 2 |
| Zamani, O | 1 |
| Böttcher, E | 1 |
| Rieger, JD | 1 |
| Mitterhuber, J | 1 |
| Hawel, R | 1 |
| Stallinger, S | 1 |
| Eller, N | 1 |
| Bello, AE | 1 |
| Kent, JD | 2 |
| Holt, RJ | 1 |
| Ruschitzka, F | 1 |
| Gaffney, M | 1 |
| Beckerman, B | 1 |
| Halen, PK | 1 |
| Murumkar, PR | 1 |
| Giridhar, R | 1 |
| Yadav, MR | 1 |
| Birk, JW | 1 |
| Myers, M | 1 |
| Nanau, RM | 1 |
| Neuman, MG | 1 |
| Huang, L | 1 |
| Mackenzie, G | 1 |
| Ouyang, N | 1 |
| Sun, Y | 1 |
| Xie, G | 1 |
| Johnson, F | 1 |
| Komninou, D | 1 |
| Rigas, B | 1 |
| McCarthy, D | 1 |
| Voelker, M | 1 |
| Brueckner, A | 1 |
| Senn, S | 1 |
| Schiff, M | 1 |
| Che, X | 1 |
| Wang, LH | 1 |
| Yang, Y | 1 |
| Yuan, Y | 1 |
| Wang, QF | 1 |
| Wang, Y | 1 |
| Li, SM | 1 |
| Doyle, G | 2 |
| Jayawardena, S | 2 |
| Ashraf, E | 2 |
| Cooper, SA | 2 |
| Moore, N | 1 |
| Fries, JF | 1 |
| Bruce, B | 1 |
| Albsoul-Younes, AM | 1 |
| Jabateh, SK | 1 |
| Abdel-Hafiz, SM | 1 |
| Al-Safi, SA | 1 |
| Lewis, JD | 1 |
| Kimmel, SE | 1 |
| Localio, AR | 1 |
| Metz, DC | 1 |
| Farrar, JT | 1 |
| Nessel, L | 1 |
| Brensinger, C | 1 |
| McGibney, K | 1 |
| Strom, BL | 1 |
| Biskupiak, JE | 1 |
| Brixner, DI | 2 |
| Howard, K | 1 |
| Oderda, GM | 1 |
| Schneeweiss, S | 1 |
| Wang, PS | 1 |
| Rassen, J | 1 |
| Leroy, S | 1 |
| Mosca, A | 1 |
| Landre-Peigne, C | 1 |
| Cosson, MA | 1 |
| Pons, G | 1 |
| Zhang, YH | 1 |
| Ji, H | 1 |
| Peng, SX | 1 |
| Singh, H | 1 |
| Hawkey, CJ | 1 |
| Weinstein, WM | 1 |
| Stricker, K | 1 |
| Murphy, V | 1 |
| Richard, D | 1 |
| Krammer, G | 1 |
| Rebuli, R | 1 |
| Bjarnason, I | 1 |
| Royer, GL | 1 |
| Seckman, CE | 1 |
| Welshman, IR | 1 |
| Wong, RC | 1 |
| Kang, S | 1 |
| Heezen, JL | 1 |
| Voorhees, JJ | 1 |
| Ellis, CN | 1 |
| Mikulaschek, WM | 1 |
| Tyson, VC | 1 |
| Glynne, A | 1 |
| Melarange, R | 2 |
| Blower, P | 1 |
| Spangler, R | 1 |
| Eversmeyer, W | 1 |
| Poland, M | 1 |
| DeLapp, RE | 1 |
| Jensen, CP | 1 |
| Poortinga, EW | 1 |
| Hungerford, LL | 1 |
| Bentkover, JD | 1 |
| Baker, AM | 1 |
| Kaplan, H | 1 |
| Kellstein, DE | 1 |
| Waksman, JA | 1 |
| Furey, SA | 1 |
| Binstok, G | 1 |
| Furey, S | 1 |
| Berlin, R | 1 |
| Cooper, S | 1 |
| Baird, L | 1 |
| Silverstein, FE | 1 |
| Faich, G | 1 |
| Goldstein, JL | 1 |
| Simon, LS | 1 |
| Pincus, T | 1 |
| Whelton, A | 1 |
| Makuch, R | 1 |
| Eisen, G | 1 |
| Agrawal, NM | 1 |
| Stenson, WF | 1 |
| Burr, AM | 1 |
| Zhao, WW | 1 |
| Lefkowith, JB | 1 |
| Verburg, KM | 1 |
| Geis, GS | 1 |
| Zuin, M | 1 |
| Podda, M | 1 |
| Selmi, C | 1 |
| Giorgini, A | 1 |
| Zermiani, P | 1 |
| Mandelli, G | 1 |
| Sacchetta, AC | 1 |
| Candiani, C | 1 |
| Watson, DJ | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 1 |
| Buisseret, PD | 1 |
| Youlten, LF | 1 |
| Heinzelmann, DI | 1 |
| Lessof, MH | 1 |
| Giansiracusa, JE | 1 |
| Donaldson, MS | 1 |
| Koonce, ML | 1 |
| Lefton, TE | 1 |
| Ruoff, GE | 1 |
| Brooks, CD | 1 |
| Valtonen, EJ | 1 |
| Busson, M | 1 |
| Ciccolunghi, SN | 1 |
| Schubiger, BI | 1 |
| Reddrop, R | 1 |
| Huskisson, EC | 1 |
| Woolf, DL | 1 |
| Balme, HW | 1 |
| Scott, J | 1 |
| Franklin, S | 1 |
| Jones, RD | 1 |
| Baynes, RE | 1 |
| Nimitz, CT | 1 |
| Gentry, C | 1 |
| O'Connell, C | 1 |
| Blower, PR | 1 |
| McElwee, NE | 1 |
| Veltri, JC | 1 |
| Bradford, DC | 1 |
| Rollins, DE | 1 |
| Schlegel, SI | 1 |
| Paulus, HE | 1 |
| Altman, R | 1 |
| Catalano, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216] | Phase 4 | 24,081 participants (Actual) | Interventional | 2006-10-04 | Completed | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators[NCT03664466] | 0 participants (Actual) | Interventional | 2021-04-29 | Withdrawn (stopped due to Inadequate funding) | |||
| Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration[NCT02380001] | Phase 4 | 60 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.[NCT01910116] | Phase 2/Phase 3 | 220 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effects on Omission of NSAIDs on the Consumption of Opioids in the Standard Analgesic Regimen After Elective Laparoscopic Colorectal Cancer Resection in an ERAS Setting. A Retrospective Single-center Cohort Study.[NCT04448652] | 502 participants (Actual) | Observational [Patient Registry] | 2015-01-01 | Completed | |||
| A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450658] | Phase 3 | 627 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450216] | Phase 3 | 906 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.[NCT04790812] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| Use of a Self-Guided Mindfulness Mobile Application to Improve Pain Outcomes in Individuals With Knee Osteoarthritis[NCT03936088] | 75 participants (Actual) | Interventional | 2019-05-02 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months
| Intervention | Number of participants (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (ITT) N= 8014, 8001, 7928 | Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325 | Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149 | Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740 | Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159 | Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846 | Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246 | Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785 | Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086 | Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635 | Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439 | Baseline (MITT) N=7974, 7954, 7894 | Change-Baseline to Mon1 MITT N=7372, 7367, 7321 | Change-Baseline to Mon2 MITT N=7170, 7078, 7142 | Change-Baseline to Mon4 MITT N=6772, 6686, 6732 | Change-Baseline to Mon8 MITT N=6224, 6128, 6155 | Change-Baseline to Mon12 MITT N=5787, 5689, 5844 | Change-Baseline to Mon18 MITT N=5305, 5175, 5242 | Change-Baseline to Mon24 MITT N=4815, 4769, 4782 | Change-Baseline to Mon30 MITT N=4139, 4067, 4085 | Change-Baseline to Mon36 MITT N=3691, 3623, 3635 | Change-Baseline to Mon42 MITT N=3468, 3404, 3438 | |
| Celecoxib | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.3 | -10.5 | -10.1 | -11.4 | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.4 | -10.5 | -10.2 | -11.4 |
| Ibuprofen | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 |
| Naproxen | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.4 | -11.3 | -11.6 | -12.1 | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.3 | -11.3 | -11.6 | -12.1 |
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 4.2 | 3.1 |
| Ibuprofen | 4.8 | 3.6 |
| Naproxen | 4.3 | 3.2 |
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months
| Intervention | Percentage of Partcipants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 2.3 | 1.7 |
| Ibuprofen | 2.7 | 1.9 |
| Naproxen | 2.5 | 1.8 |
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 0.7 | 0.3 |
| Ibuprofen | 0.9 | 0.7 |
| Naproxen | 0.7 | 0.7 |
"Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -11 |
| Placebo | -2.9 |
"Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.9 |
| Placebo | -4.8 |
"Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -6.8 |
| Placebo | -3.7 |
"Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.7 |
| Placebo | -4.8 |
"Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).~AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -2.2 |
"Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -14.6 |
| Placebo | -8.0 |
"Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -15.6 |
| Placebo | -4.4 |
"Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -13.4 |
| Placebo | -2.2 |
"Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -14.0 |
| Placebo | -11.0 |
"Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -8.0 |
"Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -6.0 |
"Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12.0 |
| Placebo | -6 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baselie and 16 weeks
| Intervention | participants (Number) |
|---|---|
| Shinbaro | 55 |
| Placebo | 40 |
"Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -11.0 |
| Placebo | -6.0 |
"Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -8.5 |
"Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -3.0 |
"Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -6.0 |
"Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -19.0 |
| Placebo | -13 |
"Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12 |
| Placebo | -6.5 |
"Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12 |
| Placebo | -7.0 |
"Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -16.0 |
| Placebo | -11.5 |
"Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -2.0 |
| Placebo | -1.0 |
"Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -2.0 |
| Placebo | -1.0 |
"Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -1 |
| Placebo | 0 |
"Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | -1.0 |
| Placebo | -1.0 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 12 weeks and 16 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 2 | 104 |
| Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 4 weeks and 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 7 | 99 |
| Shinbaro | 10 | 99 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 8 weeks and 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 4 | 102 |
| Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: Baseline 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 4 | 102 |
| Shinbaro | 7 | 102 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| responder | nonresponder | |
| Placebo | 43 | 63 |
| Shinbaro | 62 | 47 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| responder | nonresponder | |
| Placebo | 38 | 68 |
| Shinbaro | 56 | 53 |
Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Responder | Nonresponder | |
| Placebo | 32 | 74 |
| Shinbaro | 48 | 61 |
The secondary efficacy endpoint was the number of subjects with duodenal ulcer at any time throughout the 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 3 |
| Ibuprofen | 9 |
The secondary efficacy endpoint was the number of subjects with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 37 |
| Ibuprofen | 34 |
The primary efficacy endpoint was the number of subjects with upper gastrointestinal (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 40 |
| Ibuprofen | 38 |
The secondary efficacy endpoint was the number of subjects developing a NSAID-associated serious GI complication at any time throughout 6 months of treatment. A NSAID-associated serious GI complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or GI bleeding. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 0 |
| Ibuprofen | 0 |
The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 8 |
| Ibuprofen | 14 |
The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 55 |
| Ibuprofen | 52 |
The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 63 |
| Ibuprofen | 61 |
The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding. (NCT00450216)
Timeframe: 24 weeks
| Intervention | particpants (Number) |
|---|---|
| HZT-501 | 3 |
| Ibuprofen | 0 |
13 reviews available for ibuprofen and Cholera Infantum
| Article | Year |
|---|---|
To Feed or Not to Feed: A Critical Overview of Enteral Feeding Management and Gastrointestinal Complications in Preterm Neonates with a Patent Ductus Arteriosus.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus | 2019 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Therapy, Combination; Famotidine; G | 2013 |
Prodrug designing of NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Design; Gastrointestinal Diseases; Glycolates; Ibuprof | 2009 |
Ibuprofen-induced hypersensitivity syndrome.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Blood Platelets | 2010 |
Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Common Cold; Double-Blind Me | 2011 |
HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Drug Combinations | 2012 |
Forty years of ibuprofen use.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastroint | 2003 |
[Ibuprofen in childhood: evidence-based review of efficacy and safety].
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Chickenpox; Child; Gastrointes | 2007 |
[A novel class of anti-inflammatory and analgesic drugs--NO-donating NSAIDs].
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Cycloo | 2007 |
Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Gastrointestinal Diseases; Humans; Ibuprofen | 2007 |
The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Female; Gastroin | 1999 |
Non-steroidal and analgesic therapy in the elderly.
Topics: Acetaminophen; Aged; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents; Apazone; Aspirin; Cen | 1986 |
26 trials available for ibuprofen and Cholera Infantum
| Article | Year |
|---|---|
Ibuprofen Increases Markers of Intestinal Barrier Injury But Suppresses Inflammation at Rest and After Exercise in Hypoxia.
Topics: Adult; Chemokine CCL2; Exercise; Gastrointestinal Diseases; Humans; Hypoxia; Ibuprofen; Inflammation | 2023 |
A new lipid formulation of low dose ibuprofen shows non-inferiority to high dose standard ibuprofen: the FLARE study (flaring arthralgia relief evaluation in episodic flaring knee pain) - a randomised double-blind study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Capsules; Double-Blind | 2017 |
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2018 |
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspi | 2018 |
Comparison of safety, efficacy and tolerability of dexibuprofen and ibuprofen in the treatment of osteoarthritis of the hip or knee.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2014 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Efficacy and tolerability of nonprescription ibuprofen versus celecoxib for dental pain.
Topics: Adolescent; Adult; Celecoxib; Dosage Forms; Double-Blind Method; Drug Administration Schedule; Femal | 2002 |
Forty years of ibuprofen use.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastroint | 2003 |
Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Even
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cyclooxygenase | 2008 |
Safety profile: fifteen years of clinical experience with ibuprofen.
Topics: Anti-Inflammatory Agents; Aspirin; Blood Cell Count; Blood Coagulation Tests; Blood Proteins; Centra | 1984 |
Oral ibuprofen and tetracycline for the treatment of acne vulgaris.
Topics: Acne Vulgaris; Adolescent; Adult; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointe | 1984 |
Long-term safety of benoxaprofen.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Benzoxazoles; Blood Urea Nitrogen; C | 1980 |
A comparative study of benoxaprofen and ibuprofen in osteoarthritis in general practice.
Topics: Adult; Age Factors; Aged; Alkaline Phosphatase; Anti-Inflammatory Agents; Benzoxazoles; Clinical Tri | 1980 |
Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Diclofenac; | 1993 |
A decision analysis model in the evaluation of NSAIDs in a managed care setting: a case study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Decision Tre | 1994 |
The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Female; Gastroin | 1999 |
Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ch | 1999 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; | 2000 |
Gastrointestinal tolerability of ibuprofen administered in two pharmaceutical formulations.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Female; Gastric Mucosa; Gastroin | 2000 |
Prostaglandin-synthesis inhibitors in prophylaxis of food intolerance.
Topics: Acute Disease; Adult; Animals; Aspirin; Bivalvia; Chickens; Clinical Trials as Topic; Dairy Products | 1978 |
Ibuprofen in osteoarthritis.
Topics: Activities of Daily Living; Aspirin; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dextro | 1977 |
A comparative study on ibuprofen (Brufen) and indomethacin in non-articular rheumatism.
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Gastrointestinal Diseases; H | 1978 |
Four new anti-inflammatory drugs: responses and variations.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Fenoprofen; Gastrointesti | 1976 |
International experiences with diclofenac in osteoarthritis.
Topics: Aspirin; Clinical Trials as Topic; Diclofenac; Diflunisal; Double-Blind Method; Gastrointestinal Dis | 1986 |
Worldwide safety experience with diclofenac.
Topics: Adult; Aged; Aspirin; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as Topic; Diclo | 1986 |
23 other studies available for ibuprofen and Cholera Infantum
| Article | Year |
|---|---|
Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity.
Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cholesterol; Cysteine; Drug | 2004 |
Design and study of some novel ibuprofen derivatives with potential nootropic and neuroprotective properties.
Topics: Animals; Antioxidants; Arthritis, Experimental; Biphenyl Compounds; Blood-Brain Barrier; Cholesterol | 2007 |
Use of multicriteria decision analysis for assessing the benefit and risk of over-the-counter analgesics.
Topics: Analgesics; Aspirin; Decision Support Techniques; Gastrointestinal Diseases; Humans; Ibuprofen; Napr | 2017 |
Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example.
Topics: Adolescent; Adult; Aged; Algorithms; Arthritis; Celecoxib; Confounding Factors, Epidemiologic; Cyclo | 2013 |
A fixed dose combination of ibuprofen and famotidine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials, Phase III as Topic; Dru | 2009 |
The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Aspirin; Cell Line; Cytok | 2011 |
Ibuprofen ion-exchange fiber complex: improved dissolution and gastric tolerance based on ion exchange.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Drug Carriers; Drug-Rel | 2013 |
Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Dose-R | 2003 |
Awareness and frequency of potential side effects on nonsteroidal anti-inflammatory drugs among the Jordanian patient population.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Awareness; Diclofenac; Drug Utilization; | 2004 |
Risk of serious upper gastrointestinal toxicity with over-the-counter nonaspirin nonsteroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Gastrointestinal Diseases; Gastrointestinal He | 2005 |
Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; | 2006 |
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; F | 2006 |
Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dicl | 2007 |
Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Clinical | 2007 |
Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Carrageen | 1994 |
A case-control study of acute ibuprofen toxicity in dogs.
Topics: Acute Kidney Injury; Animals; Case-Control Studies; Dog Diseases; Dogs; Duodenal Ulcer; Female; Gast | 1998 |
Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol.
Topics: Aged; Butanones; Cost-Benefit Analysis; Direct Service Costs; Drug Therapy, Combination; Gastrointes | 1994 |
[Side effects cause enormous costs. Expensive arthritis therapy].
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Celecoxib; | 2001 |
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials | 2001 |
Comparisons of tolerability findings in international clinical trials.
Topics: Arthritis, Rheumatoid; Aspirin; Cardiovascular System; Clinical Trials as Topic; Diclofenac; Drug To | 1979 |
Nonsteroidal anti-inflammatory drug toxicosis in dogs and cats: 240 cases (1989-1990)
Topics: Accidents; Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cat Diseases; C | 1992 |
Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Butanones; Carrageenan; Diclofenac; E | 1991 |
A prospective, population-based study of acute ibuprofen overdose: complications are rare and routine serum levels not warranted.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cohort Studies; Female; Gastrointestinal Diseases; | 1990 |